Table 4.
Effect of MLE, GEE and CFE supplementation on heart SIRT1 pathway (p-AMPK-α, SIRT1, PGC1-α and p-FOXO3) mRNA expression in AD mice.
| Enzyme | Enzyme/β-actin | ||||
|---|---|---|---|---|---|
| Control | AD | AD + MLE | AD + GEE | AD + CFE | |
| p-AMPK-α | 1.00 ± 0.13 b | 2.56 ± 0.12 a | 1.23 ± 0.39 b | 1.33 ± 0.27 b | 1.23 ± 0.65 b |
| SIRT1 | 1.00 ± 0.22 b | 2.21 ± 0.23 a | 3.56 ± 0.65 b | 4.46 ± 0.52 b | 3.21 ± 0.53 b |
| PGC1-α | 1.00 ± 0.35 b | 2.65 ± 0.35 a | 1.33 ± 0.29 b | 1.43 ± 0.27 b | 1.31 ± 0.15 b |
| p-FOXO3 | 1.00 ± 0.16 b | 2.36 ± 0.27 a | 1.23 ± 0.19 b | 1.35 ± 0.25 b | 1.13 ± 0.33 b |
All the data showed here are the ratios of each enzyme to β-actin according to the quantitative and statistical results of RT-PCR from densitometric analysis. (a–c) Values represent mean ± SD (n = 8), and values different superscripts are significantly different (p < 0.05). AD, Alzheimer’s disease; MLE, Meretrix lusoria; GEE, Geloina eros; CFE, Corbicula fluminea.